Hosted on MSN
Denali Therapeutics’ ALS therapy fails to meet primary endpoint in Phase II/III trial
US-based biotechnology company Denali Therapeutics has reported that a Phase II/III trial of DNL343 for amyotrophic lateral sclerosis (ALS) failed to meet its primary endpoint. The primary analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback